Van ECK Associates Corp Purchases 7,509 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Van ECK Associates Corp lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 13.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 64,337 shares of the biopharmaceutical company's stock after acquiring an additional 7,509 shares during the quarter. Van ECK Associates Corp owned approximately 0.06% of Regeneron Pharmaceuticals worth $56,507,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in REGN. FMR LLC grew its stake in shares of Regeneron Pharmaceuticals by 7.3% during the third quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company's stock worth $8,098,661,000 after purchasing an additional 669,517 shares during the period. International Assets Investment Management LLC grew its position in shares of Regeneron Pharmaceuticals by 76,169.5% during the 4th quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company's stock worth $519,148,000 after buying an additional 590,314 shares during the period. abrdn plc increased its stake in shares of Regeneron Pharmaceuticals by 552.8% in the 4th quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company's stock valued at $193,136,000 after acquiring an additional 186,215 shares during the last quarter. Assenagon Asset Management S.A. raised its position in shares of Regeneron Pharmaceuticals by 129.3% in the 4th quarter. Assenagon Asset Management S.A. now owns 216,523 shares of the biopharmaceutical company's stock valued at $190,170,000 after acquiring an additional 122,103 shares during the period. Finally, TD Asset Management Inc boosted its stake in Regeneron Pharmaceuticals by 64.4% during the 3rd quarter. TD Asset Management Inc now owns 180,267 shares of the biopharmaceutical company's stock worth $148,353,000 after acquiring an additional 70,628 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Down 0.2 %

REGN traded down $1.82 during trading on Tuesday, reaching $890.66. 627,942 shares of the stock were exchanged, compared to its average volume of 491,369. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The stock's 50 day moving average price is $945.77 and its two-hundred day moving average price is $895.19. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $998.33. The stock has a market cap of $97.76 billion, a P/E ratio of 25.63, a price-to-earnings-growth ratio of 2.54 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same period in the previous year, the business earned $10.96 EPS. Regeneron Pharmaceuticals's revenue for the quarter was up .6% compared to the same quarter last year. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current year.

Analyst Ratings Changes

REGN has been the subject of several recent analyst reports. UBS Group upped their target price on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a "buy" rating in a research note on Wednesday, April 17th. BMO Capital Markets lifted their target price on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an "outperform" rating in a report on Monday, February 5th. Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an "outperform" rating and a $1,125.00 price target for the company. Cantor Fitzgerald reiterated a "neutral" rating and set a $925.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, April 15th. Finally, Barclays increased their target price on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 23rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $977.77.

Insider Transactions at Regeneron Pharmaceuticals

In other news, EVP Marion Mccourt sold 1,000 shares of the firm's stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the sale, the executive vice president now owns 13,789 shares in the company, valued at approximately $12,888,716.19. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $954.22, for a total transaction of $95,422.00. Following the completion of the sale, the director now owns 18,382 shares of the company's stock, valued at $17,540,472.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Marion Mccourt sold 1,000 shares of the company's stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the transaction, the executive vice president now owns 13,789 shares in the company, valued at $12,888,716.19. The disclosure for this sale can be found here. In the last three months, insiders sold 10,195 shares of company stock worth $9,759,898. 8.83% of the stock is owned by company insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.